Elite Pharmaceuticals Inc (ELTP)

[tangerine]

Eaglet is interesting and they have cash but they also are losing 10m per Q and have almost twice as many shares as noted if diluted and zero revenues.

Elite's development costs are way lower and a real advantage as well as the generation of revenues to support costs. If anything Eaglet shows just how undervalued Elite currently is. That was just a quick look at it.

From a trial perpsective, it would seem they are pretty far behind ELite